# Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

> **NCT00237627** · PHASE1,PHASE2 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 107 (actual)

## Conditions studied

- Breast Cancer
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Ovarian Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** PS-341
- **DRUG:** Doxil
- **DRUG:** Velcade

## Key facts

- **NCT ID:** NCT00237627
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2006-12
- **Final completion:** 2010-01
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2012-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237627, "Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00237627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*